12.05.11 - XBiotech Presents Oncology Trial Results
XBiotech recently presented results from its oncology program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. This important conference brings together over 3000 professionals and highlights new discoveries and novel therapeutics in cancer research. Medical Director Michael Stecher M.D. and Principle Investigator David Hong M.D presented the exciting results from the three-week dosing cohort of XBiotech’s ongoing trial of MABp1 in advanced cancers. “It was very satisfying to finally be able to share these results with the rest of the oncology research community. We feel that our lead antibody represents a breakthrough in oncology therapy” reflects Dr. Stecher.
Accepted abstracts from the conference are reprinted in an online-supplement to the journal Molecular Cancer Therapeutics. For more information, please contact: mstecher@xbiotech.com.
© 2012 XBiotech USA, Inc. | All Rights Reserved